SCHEMBL24153613

SCHEMBL24153613

CCc1sc2ccccc2c1CN1CCN2C(=O)CN(Cc3ccc(-c4ccccc4)cc3)C(=O)C2C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY1R P25929 2/20 0.36
▸ ENPP2 Q13822 1/20 0.36
▸ GRM2 Q14416 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ THRB P10828 2/20 0.34
▸ FAAH O00519 1/20 0.34
▸ MGLL Q99685 1/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ MAPT P10636 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ PDE4A P27815 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ PDE3B Q13370 1/20 0.33
▸ PDE7A Q13946 1/20 0.33
▸ PDE3A Q14432 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24153475 0.95 KMT2A (0.38) NPY1RHTR1ALMNATHRBKMT2A
SCHEMBL24938892 0.92 NPY1R (0.41) NPY1RHTR1ALMNATHRBSMN1; SMN2
SCHEMBL24939891 0.92 LMNA (0.42) NPY1RHTR1ALMNATHRBKMT2A
SCHEMBL24939973 0.91 NPY1R (0.36) NPY1RHTR1ALMNATHRBMAPT
SCHEMBL24939892 0.91 LMNA (0.38) NPY1RHTR1ALMNATHRBMAPT
SCHEMBL24153499 0.91 HTR1A (0.39) NPY1RHTR1A
SCHEMBL24939924 0.90 L3MBTL1 (0.41) NPY1RKMT2ASMN1; SMN2MAPTL3MBTL1
SCHEMBL23334412 0.89 MAPT (0.35) NPY1RHTR1ALMNATHRBFAAH
SCHEMBL24938971 0.89 NPY1R (0.39) NPY1RHTR1ALMNATHRB
SCHEMBL24153472 0.88 HTR1A (0.39) NPY1RHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019094-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME HOLOSMEDIC (KR) 2023-01-19 — — US disclosed
WO-2021261969-A1 PREPARATION METHOD FOR NOVEL COMPOUND 홀로스메딕 주식회사 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019094-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 NPY1R 4531/4885ENPP2 2123/4885GRM2 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback